Examples of 'gefitinib' in a sentence
Meaning of "gefitinib"
Gefitinib (adjective) - Refers to a drug that is classified as an epidermal growth factor receptor (EGFR) inhibitor, commonly used in cancer treatment
Show more definitions
- A drug, used in the treatment of certain types of cancer, that acts in a similar way to erlotinib by selectively targeting the mutant proteins in malignant cells.
How to use "gefitinib" in a sentence
Basic
Advanced
gefitinib
Exposure to gefitinib is not significantly altered by food.
It is the target of the cancer drug gefitinib.
It is not known whether gefitinib is secreted in human milk.
This could decrease the effectiveness of gefitinib.
Gefitinib did not prolong survival in the overall population.
Both interactions were disrupted in the presence of gefitinib.
Chemical structures of gefitinib and erlotinib.
Gastrointestinal perforation has been reported in patients taking gefitinib.
Gefitinib is extensively metabolised in humans.
There is no specific treatment in the event of overdose of gefitinib.
Gefitinib showed no genotoxic potential.
Examples of biological therapies include erlotinib and gefitinib.
Gefitinib appears to be effective in treating brain metastases in a subgroup of patients.
Cells were treated with different concentrations of gefitinib or erlotinib.
Clinical trial of gefitinib for advanced lung cancer closes early.
See also
Iressa is a medicine that contains the active substance gefitinib.
Active substances that may increase gefitinib plasma concentrations.
It is therefore considered unlikely that it contributes to the clinical activity of gefitinib.
Active substances that may reduce gefitinib plasma concentrations.
Prominent examples are the tyrosine kinase inhibitors imatinib and gefitinib.
There are no data from the use of gefitinib in pregnant women.
Active substances that may have their plasma concentrations altered by gefitinib.
Gefitinib plus best supportive care was compared to placebo plus best supportive care.
The active substance is gefitinib.
Gefitinib was obtained from commercial sources and was purified through an ethyl acetate extraction.
Drugs that elevate gastric pH can reduce gefitinib levels.
Gefitinib has a favourable toxicity profile when compared with current chemotherapy regimens.
Age and disease stage had no correlation with gefitinib activity.
Erlotinib and gefitinib are chemotherapeutic agents which belong to the group of medicines called antineoplastics.
This alternative splicing switch modulates autophagic activity of the cells in reponseto gefitinib.
The results of an in vitro phototoxicity study demonstrated that gefitinib may have phototoxicity potential.
Dacomitinib is associated with more adverse events and may need more dose reductions than gefitinib.
The same goes for gefitinib inhibition of Bcrp.
These mutations tend to increase sensitivity to tyrosine kinase inhibitors including gefitinib and erlotinib.
The effectiveness of Gefitinib is based on objective response rates.
These findings suggest that the mutant receptor is more sensitive to the effects of gefitinib.
A Values presented are for gefitinib versus docetaxel.
These will help you and your doctors decide if you are likely to benefit from gefitinib.
A Values presented are for gefitinib versus placebo.
An exemplary small molecule inhibitor of EGFR signaling comprises gefitinib.
The dosage of Gefitinib prescribed to each patient will vary.
Survival curve of cells treated with HGF and gefitinib.
Gefitinib and erlotinib were both shown to inhibit EGFR tyrosine phosphorylation.
In some embodiments the EGFR tyrosine kinase inhibitor is erlotinib or gefitinib.
Gefitinib Mylan should not be used during pregnancy unless clearly necessary.
Summary of genetic changes in NSCLC patients with acquired resistance to gefitinib or erlotinib.
Gefitinib or chemotherapy for non small cell lung cancer with mutated EGFR.
Clinical experience has not shown a causal association between QT prolongation and gefitinib.
EGFR mutations which were associated with resistance to gefitinib and erlotinib were also identified.
These mutations result in increased in vitro activity of EGFR and increased sensitivity to gefitinib.
